Cargando…
Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond
Systemic therapy for hepatocellular carcinoma (HCC) has markedly advanced since the survival benefit of a molecular targeted agent, sorafenib, were demonstrated in the SHARP and Asia Pacific trials in 2007. Treatment options for patients with advanced HCC increased by sorafenib, and long-term surviv...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Baishideng Publishing Group Inc
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385008/ https://www.ncbi.nlm.nih.gov/pubmed/30809080 http://dx.doi.org/10.3748/wjg.v25.i7.789 |